

Technology Appraisal Committee Meeting (Committee B)

Minutes: Confirmed

Date and Time: Tuesday 6 November 2018, from 10am to 5.30pm

Venue: 10 Spring Gardens
London
SW1A 2BU

Present:	1. Dr Amanda Adler (Chair) 2. Dr Sanjeev Patel (Vice-Chair, Chaired notes 3. Dr Carlo Berti 4. Professor John Cairns 5. Mr Mark Chapman 6. Mr Diar Fattah 7. Ms Susan Faulds 8. Mr Richard Hoddes 9. Dr Sanjay Kinra 10. Dr Nicholas Latimer 11. Mr Christopher O'Regan 12. Professor Stephen Palmer 13. Professor Allyson Pollock 14. Dr Stephen Smith 15. Mr William Turner 16. Professor Nicky Welton 17. Mr Nigel Westwood 18. Professor Sarah Wild 19. Dr Stuart Williams	Present for all notes Present for notes 1 to 17 (as a Committee member) and for notes 18 to 28 (as an ERG representative) Present for notes 1 to 39 Present for all notes Present for all notes
-----------------	---	---

In attendance:

Helen Knight	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Dr Melinda Goodall	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Joanne Ekeledo	Project Manager, National Institute for Health and Care Excellence	Present for all notes

Sandra Aleknavice	Administrator, National Institute for Health and Care Excellence	Present for all notes
Alan Lamb	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 1 to 17
Jamie Elvidge	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes 1 to 30
Adam Brooke	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 18 to 30
Dr Mary Hughes	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 31 to 43
Ahmed Elsada	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes 31 to 43
Lindsay Claxton	Research Fellow in Health Economics, Centre for Reviews and Dissemination and Centre for Health Economics – York	Present for notes 1 to 15
Sahar Sharif	Health Economist, Centre for Reviews and Dissemination and Centre for Health Economics – York	Present for notes 1 to 15
Matthew Walton	Research Fellow, Centre for Reviews and Dissemination and Centre for Health Economics – York	Present for notes 1 to 15
Stephen Palmer	Professor of Health Economics, Centre for Reviews and Dissemination and Centre for Health Economics – York	Present for notes 18 to 28 (as an ERG representative)
Mark Corbett	Research Fellow, Centre for Reviews and Dissemination and Centre for Health Economics – York	Present for notes 18 to 28

Francesco Fusco	Research Fellow, Centre for Reviews and Dissemination and Centre for Health Economics – York	Present for notes 18 to 28
Dr Anthony Bewley	Consultant Dermatologist Whips Cross University Hospital – clinical expert, nominated UCB	Present for notes 5 to 13
Dr Hector Chinoy	Senior Lecturer and Honorary Consultant Rheumatologist, University of Manchester – clinical expert, nominated UCB	Present for notes 5 to 13
Dr Andrew Pink	Consultant Dermatologist St. John's Institute of Dermatology, Guy's & St. Thomas' NHS Trust – clinical expert, nominated by Amirall	Present for notes 18 to 26
Mr David Chandler	Patient expert, nominated by the Psoriasis and Psoriatic Arthritis Alliance (PAPAA)	Present for notes 5 to 13 and for notes 18 to 26
Ms Helen McAteer	Patient expert, nominated by the Psoriasis Associated	Present for notes 5 to 13 and for notes 18 to 26
Professor Joanne Lord	Director, Southampton Health Technology Assessment Centre	Present for notes 31 to 39
Dr Jo Picot	Senior Research Fellow, Southampton Health Technology Assessment Centre	Present for notes 31 to 39

Non-public attendees:

Yelan Guo	Technical Advisor, NICE	Present for all notes
Gareth Hooper	New Committee member	Present for all notes
Rufaro Kausi	Technical Advisor, NICE	Present for all notes
Pilar Pinilla-Dominguez	Technical Advisor, NICE	Present for notes 31 to 43
Priya Modha	Chief Pharmaceutical Officer's Clinical Fellow, NICE	Present for all notes
Paul Weinberger	Commercial Negotiation Principal, NHS England	Present for all notes
Helen Barnett	Medical Editor, NICE	Present for all notes
Edgar Masanga	Business Analyst, NICE	Present for all notes

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of certolizumab pegol for treating chronic plaque psoriasis [ID1232], tildrakizumab for treating chronic plaque psoriasis after systemic therapy [ID1060] and daratumumab in combination with bortezomib for treating relapsed or refractory multiple myeloma [ID974].
2. The Chair informed the Committee of the non-public observers at this meeting: Yelan Guo, Gareth Hooper, Rufaro Kausi, Priya Modha, Paul Weinberger, Helen Barnett and Edgar Masanga.
3. Apologies were received from Dr Mark Glover and Dr Mona Johnson

Any other Business

4. The Committee were given an update on the progress and timelines for other appraisals they have considered at previous meetings.

Appraisal of certolizumab pegol for treating chronic plaque psoriasis [ID1232]

Part 1 – Open session

5. The Chair welcomed the invited experts: Lindsay Claxton, Sahar Sharif, Matthew Walton, Dr Anthony Bewley, Dr Hector Chinoy, Mr David Chandler and Ms Helen McAteer to the meeting and they introduced themselves to the Committee.
6. The Chair welcomed company representatives from UCB to the meeting.
7. The Chair asked all Committee members to declare any relevant interests
 - 7.1. Dr Amanda Adler, Dr Sanjeev Patel, Dr Carlo Berti, Professor John Cairns, Mr Mark Chapman, Mr Diar Fattah, Ms Susan Faulds, Mr Richard Hoddes, Dr Sanjay Kinra, Dr Nicholas Latimer, Professor Stephen Palmer, Professor Allyson Pollock, Dr Stephen Smith, Mr William Turner, Professor Nicky Welton, Mr Nigel Westwood, Professor Sarah Wild and Dr Stuart Williams all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of certolizumab pegol for treating chronic plaque psoriasis [ID1232].
 - 7.2. Mr Chris O'Regan declared a personal specific financial interest before the meeting as he is employed by Merck Sharp and Dohme.
 - 7.2.1. It was agreed that Mr O'Regan would not take part in this appraisal.
8. The Chair asked all NICE Staff to declare any relevant interests.
 - 8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of certolizumab pegol for treating chronic plaque psoriasis [ID1232].

9. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
 - 9.1. Lindsay Claxton, Sahar Sharif, Matthew Walton and Mr David Chandler declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of certolizumab pegol for treating chronic plaque psoriasis [ID1232].
 - 9.2. Dr Anthony Bewley declared a non-personal specific financial interest as he has worked on ad hoc consultancies with a number of pharmaceutical companies, including Leo Pharma.
 - 9.2.1. It was agreed that this declaration would not prevent Dr Bewley from participating in this section of the meeting.
 - 9.3. Dr Hector Chinoy declared a personal specific financial interest as he has received advisory board or lecture fees from Lilly, UCB, Janssen and Biogen, undertaken consultancy work for Momenta and Novartis and received travel support from Abbvie and Janssen.
 - 9.3.1. It was agreed that this declaration would not prevent Dr Chinoy from participating in this section of the meeting.
 - 9.4. Mrs Helen McAteer declared a personal specific financial interest as the Psoriasis Association has six corporate members.
 - 9.4.1. It was agreed that this declaration would not prevent Mrs McAteer from participating in this section of the meeting.
10. The Chair introduced the lead team, Dr Carlo Berti, Dr Stephen Smith and Mr Nigel Westwood who gave presentations on the clinical effectiveness and cost effectiveness of certolizumab pegol for treating chronic plaque psoriasis [ID1232].
11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
12. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.
13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

14. Discussion on confidential information continued. This information was supplied by the company.
15. The Chair then thanked the Evidence Review Group representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

16. The Committee continued to discuss the clinical and cost effectiveness of certolizumab pegol for treating chronic plaque psoriasis [ID1232].
 - 16.1. The committee decision was based on consensus.
17. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Appraisal of tildrakizumab for treating chronic plaque psoriasis after systemic therapy [ID1060]

Part 1 – Open session

18. The Chair welcomed the invited experts: Stephen Palmer, Mark Corbett, Francesco Fusco, Dr Andrew Pink, Mr David Chandler and Ms Helen McAteer to the meeting and they introduced themselves to the Committee.
19. The Chair welcomed company representatives from Almirall to the meeting.
20. The Chair asked all Committee members to declare any relevant interests
 - 20.1. Dr Amanda Adler, Dr Sanjeev Patel, Dr Carlo Berti, Professor John Cairns, Mr Mark Chapman, Mr Diar Fattah, Ms Susan Faulds, Mr Richard Hoddes, Dr Sanjay Kinra, Dr Nicholas Latimer, Professor Allyson Pollock, Dr Stephen Smith, Mr William Turner, Professor Nicky Welton, Mr Nigel Westwood, Professor Sarah Wild and Dr Stuart Williams all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of tildrakizumab for treating chronic plaque psoriasis after systemic therapy [ID1060].
 - 20.2. Mr Chris O'Regan declared a personal specific financial interest before the meeting as he is employed by Merck Sharp and Dohme.
 - 9.2.1 It was agreed that Mr O'Regan would not take part in this appraisal.
21. The Chair asked all NICE Staff to declare any relevant interests.
 - 21.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of tildrakizumab for treating chronic plaque psoriasis after systemic therapy [ID1060].
22. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
 - 22.1. Stephen Palmer, Mark Corbett, Francesco Fusco, Dr Andrew Pink, Mr David Chandler and Ms Helen McAteer declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered

as part of the appraisal of tildrakizumab for treating chronic plaque psoriasis after systemic therapy [ID1060].

22.2. Dr Anthony Bewley declared a non-personal specific financial interest as he has worked on ad hoc consultancies with a number of pharmaceutical companies.

22.2.1. It was agreed that this declaration would not prevent Dr Bewley from participating in this section of the meeting

22.3. Mrs Helen McAteer declared a personal specific financial interest as the Psoriasis Association has six corporate members.

22.3.1. It was agreed that this declaration would not prevent Mrs McAteer from participating in this section of the meeting.

23. The Chair introduced the lead team, Dr Sarah Wild, Dr Stephen Smith and Mr Nigel Westwood who gave presentations on the clinical effectiveness and cost effectiveness of tildrakizumab for treating chronic plaque psoriasis after systemic therapy [ID1060].

24. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

25. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.

26. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

27. Discussion on confidential information continued. This information was supplied by the company.

28. The Chair then thanked the Evidence Review Group representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

29. The Committee continued to discuss the clinical and cost effectiveness of tildrakizumab for treating chronic plaque psoriasis after systemic therapy [ID1060].

29.1. The committee decision was based on consensus.

30. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Appraisal of daratumumab in combination with bortezomib for treating relapsed or refractory multiple myeloma [ID974]

Part 1 – Open session

31. The Chair welcomed the invited experts: Professor Joanne Lord and Dr Jo Picot to the meeting and they introduced themselves to the Committee.

32. The Chair welcomed company representatives from Janssen to the meeting.
33. The Chair asked all Committee members to declare any relevant interests
 - 33.1. Dr Amanda Adler, Dr Sanjeev Patel, Dr Carlo Berti, Professor John Cairns, Mr Mark Chapman, Mr Diar Fattah, Ms Susan Faulds, Mr Richard Hoddes, Dr Sanjay Kinra, Dr Nicholas Latimer, Mr Christopher O'Regan, Professor Allyson Pollock, Dr Stephen Smith, Mr William Turner, Professor Nicky Welton, Mr Nigel Westwood, Professor Sarah Wild and Dr Stuart Williams all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of daratumumab in combination with bortezomib for treating relapsed or refractory multiple myeloma [ID974]
 - 33.2. Professor Stephen Palmer declared a non-personal specific financial interest before the meeting as he has received consultancy fees from Amgen for general technical advice.
 - 33.2.1. It was agreed that this declaration would prevent Professor Palmer from participating in this section of the meeting.
34. The Chair asked all NICE Staff to declare any relevant interests.
 - 34.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of daratumumab in combination with bortezomib for treating relapsed or refractory multiple myeloma [ID974].
35. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
 - 35.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of daratumumab in combination with bortezomib for treating relapsed or refractory multiple myeloma [ID974].
36. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
37. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
38. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be

prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.

39. The Chair then thanked the Evidence Review Group and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

40. Discussion on confidential information continued. This information was supplied by the company.
41. The Committee continued to discuss the clinical and cost effectiveness of daratumumab in combination with bortezomib for treating relapsed or refractory multiple myeloma [ID974].
 - 41.1. The committee decision was based on consensus.
42. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

43. Tuesday 4 December 2018 at 10 Spring Gardens, London SW1A 2BU